The US FDA has scheduled a meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) for Wednesday, December 9, 2015. The committee will discuss biologics license application 761033, reslizumab for injection, submitted by Teva Pharmaceutical Industries, Ltd., for the proposed indication to reduce exacerbations, relieve symptoms, and improve lung function in adults and adolescents 12 years of age and above, with asthma and elevated blood eosinophils, who are inadequately controlled on inhaled corticosteroids.

See the FDA announcement